



## Resolution n°2-2020-e

### **Global long-acting drug combination development (GLAD) project: transformation of oral short-acting TLD to long-acting injectable products**

Recalling Unitaid Executive Board Resolution n°14-2019-e of 18 July 2019, in which the Board provided its go-ahead for the development by the Unitaid Secretariat of a full grant agreement package for the proposed Project '*Repurposing oral TLD (tenofovir disoproxil fumarate, lamivudine, dolutegravir) to a long-acting injectable combination HIV medicine using a novel technology*' (the "Project");

The Executive Board now authorizes the Secretariat to commit up to US\$ 6,962,027 for the Project, subject to availability of funds.

Funding is conditional upon signature of the grant agreement between Unitaid and the University of Washington.

**Lead Organization:** University of Washington

**Project Duration:** 4 years

Marisol Touraine  
Chair of the Unitaid Executive Board

Date: 17.01.2020